Milken Institute School of Public Health site logo

Milken Institute School of Public Health

 

DC Cohort Longitudinal HIV Status Neutral Study

The primary project goal is to contribute to improving the quality of care and treatment of people receiving HIV prevention services and HIV care at clinics in the District of Columbia by:

  • Linking data from multiple treatment sites to enable evaluation of HIV prevention services and HIV care provided in the District of Columbia
  • Monitoring socio-demographic data, clinical status, and treatment regimens of people receiving HIV prevention services or HIV care in DC over time
  • Providing clinic sites with routine reports on their patient population that enables them to benchmark and improve their standards of clinical care
  • Contributing to the research of emerging issues in the prevention, treatment, and long-term effects of people both living with HIV and those receiving HIV prevention services
  • Evaluating the impact of HIV screening and prevention programs in collaboration with the DC Department of Health
  • Creating a resource to facilitate additional HIV research and assist in identifying patients for research studies

The project's scientific objectives are to contribute to the knowledge regarding people receiving HIV prevention services and HIV treatment through:

  • Evaluating the outcomes of HIV medications for prevention and treatment over time
  • Examining HIV resistance patterns over time in relationship to treatment patterns and patient characteristics among people diagnosed with HIV
  • Assessing the extent and impact of co-morbidities, such as hepatitis, diabetes, lipidemia, and Sexually Transmitted Infections (STIs), on clinical outcomes among people diagnosed with HIV compared to those at higher likelihood of acquiring HIV
  • Advancing research on emerging issues in HIV Prevention and HIV disease and its treatment
About

The George Washington University (GWU) Department of Epidemiology and the GWU Biostatistics Center (BSC) together form the DC Cohort Data and Statistics Coordinating Center (DSCC). The DSCC is responsible for management and analysis of data for the DC Cohort.

The DC Cohort Executive Committee (EC) coordinates the overall direction of the study in conjunction with the Partnership for AIDS Progress (PFAP) Executive Committee and the DC Health HIV/AIDS Hepatitis, STD, TB Administration.

The DC Cohort EC members include:

  1. Principal Investigator (PI)
  2. Senior Co-Principal Investigator
  3. Project Director
  4. Representatives from the National Institutes of Health (NIH)
  5. Senior Deputy Director of the DC Health HIV/AIDS, Hepatitis, STD and TB Administration
  6. 14 Site Principal Investigators
  7. Two patient Community Advisory Board (CAB) representatives
EXECUTIVE COMMITTEE MEMBERS
Name
Title
Amanda D. Castel, MD, MPHDC Cohort Principal Investigator, The Milken Institute School of Public Health
Anne Monroe, MD, MSPHDC Cohort Co-Investigator & Project Director, The Milken Institute School of Public Health
Alan E. Greenberg, MD, MPHDC Cohort Senior Co-Investigator, The Milken Institute School of Public Health
Carl W. Dieffenbach, PhDDirector, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Henry Masur, MDChief, Critical Care Medicine Department, Clinical Center, National Institutes of Health
Clover Barnes, RN, BSN, MBASenior Deputy Director, DC Department of Health HIV/AIDS, Hepatitis, STD, and TB Administration (HAHSTA)
Stephen Abbott, MDSite Principal Investigator, Whitman-Walker Institute
Rita Aidoo, DOSite Principal Investigator, Family Medical and Counseling Service
Suyanna Barker, PhDSite Principal Investigator, La Clinica Del Pueblo
Debra Benator, MDSite Principal Investigator, Veterans Affairs Medical Center
Jose Bordon, MD, PhDSite Principal Investigator, Washington Health Institute (formerly Providence Hospital)
Rachel Denyer, MDSite Principal Investigator, Veterans Affairs Medical Center
Jhansi L. Gajjala, MDSite Principal Investigator, Howard University Hospital (Adult Infectious Disease Clinic)
DeMarc Hickson, PhDExecutive Director, Us Helping Us, People Into Living, Inc.
Michael Horberg, MDSite Principal Investigator, Kaiser Permanente Mid-Atlantic States
Adam Klein, MDSite Principal Investigator, Washington Hospital Center
Princy N. Kumar, MDSite Principal Investigator, Georgetown University
Jose Lucar, MDSite Principal Investigator, The George Washington University Medical Faculty Associates
Natella Rakhmanina, MD, PhDSite Principal Investigator, Children's National Hospital (Pediatric Clinic)
Sohail Rana, MDSite Principal Investigator, Howard University Hospital (Pediatric Clinic)
Gebeyehu Teferi, MDSite Principal Investigator, Unity Health Care
Participant Information

The DC Cohort is open to enrollment for patients receiving prevention services or care for HIV at one or more of the fourteen participating clinics. In order to join the DC Cohort, patients must be at least 18 years of age. Patients who are minors can also join but they must either be consented by a parent or legal guardian or be teenagers seeking care independently. All patients must be able to understand and sign the informed consent form. Consent forms are available in multiple languages including English, Spanish, French, Amharic, Chinese, Korean, and Vietnamese.

Participant FAQs
What is the DC Cohort?

The DC Cohort is a research project that is collecting health information on people who are receiving HIV prevention services or HIV care at clinics in the District of Columbia. The information collected will help healthcare providers find out more about HIV prevention and HIV treatment with the goal of improving HIV prevention services and HIV care for patients not only in DC, but for patients everywhere.

What is a cohort?

A "cohort" is a group of people who have something in common and who are followed over time. The "cohort" in this research project includes people with or without HIV who are receiving prevention services or HIV care in clinics throughout DC.

Which clinics are involved in this research project?

Many of the main HIV care providers in DC are taking part in this research project including:

The DC Department of Health is also taking part in this research project.

Who is paying for and leading this research project?

The DC Cohort is being paid for by the National Institutes of Health (NIH) and is being run by the Department of Epidemiology (DEPI) and the Biostatistics Center (BSC) at The Milken Institute School of Public Health.

What do I have to do to be in this research project?

To be in this research project, you must be getting HIV prevention services or receiving HIV care from at least one of the DC Cohort participating clinics, give your permission, and sign the consent form allowing researchers to confidentially combine your health information with information from thousands of other persons getting care in DC.

You will not have to come to the clinic for extra appointments or visits. You can complete the consent process during your regularly scheduled appointment at the clinic.

Do I have to be part of this research project?

No, you do not have to be part of the DC Cohort if you do not want to be. Nothing about the care that you get at your clinic will change if you are not in this research project. However, we are encouraging all persons with or without HIV to be a part of this research project so that we can get a complete picture of HIV prevention services and HIV care and treatment in DC and find better ways to care for all persons.

Who will have access to information collected through this research project that could identify me?

Only the staff the clinic at which you are receiving care and at the DC Health who already have this information will have access to it.

How will my information be kept private?

All information will be kept in a safe and secure database.

What if I change my mind after I decide to be a part of the research project?

You can change your mind at any time. If you decide to cancel your permission, you can get a withdrawal form from your clinic and give it to your health care provider. When you cancel, no additional information will be shared about you.

Do I have to pay or will I get paid if I am in this research project?

No, you do not have to pay and will not get paid if you are in this research project. If you are asked to participate in certain substudies of the DC Cohort, you may be offered an incentive.

How can I join this research project?

Someone at the clinic where you are receiving care will ask you to join the DC Cohort. If you want to join, they can tell you more about it and answer any questions you might have. If you decide to join, they will review the consent form with you.

Who do I contact for more information?

For more information, please contact your health care provider at the clinic where you are currently receiving care.

Community Advisory Board

A Community Advisory Board (CAB) has been convened to provide input and guidance on aspects of the study protocols and procedures from the patient perspective. The CAB consists of patient representatives from each clinical site. The mission of the DC Cohort CAB is to:

  • Provide recommendations and feedback regarding recruitment, retention, and ethical issues associated with the study
  • Share patient perspectives on the study with the DC Cohort leadership
  • Make recommendations about how to communicate the outcomes of the study to the involved patient populations

Additionally, two members of the CAB serve as ad hoc members of the DC Cohort Executive Committee (EC) and are responsible for communicating and sharing information between the CAB and the EC.

Interested in joining the Community Advisory Board (CAB)?

If you would like to provide community feedback on research related to the care of people who receive HIV prevention services or HIV care at one of our participating sites, you may be eligible to join the DC Cohort CAB. The purpose of our CAB is to: 

  • Build a relationship between researchers and the community
  • Receive regular updates on the DC Cohort study progress
  • Provide community perspectives and guidance on new research

Please contact James Peterson at [email protected] or Shannon Hammerlund at mailto:[email protected]. We keep all calls and correspondence confidential. CAB attendees will receive a small stipend.

Investigator Information

DC Cohort investigators are encouraged to develop ideas for analyzing both site-specific and Cohort-wide data. Please see the applicable forms pertaining to data access and publication.

Acknowledgements

The "DC Cohort Investigators" should be acknowledged whenever reference is made to the design and conduct of the study. This standard boilerplate includes the DC Cohort Principal Investigators, the DC Cohort Co-Investigator, the DC Cohort Project Director, the Senior Deputy Director of the DC Department of Health HIV/AIDS, Hepatitis, STD and TB Administration, and all DC Cohort Site PIs. Local site co-investigators may be added to the boilerplate at the discretion of the Executive Committee. This boilerplate may change over time as members leave or join the team; the Data and Statistics Coordinating Center (DSCC) will maintain an up-to-date, standard boilerplate for this purpose.

For all publications, the acknowledgement section should read the following:

Data in this manuscript were collected by the DC Cohort Study Group with investigators and research staff located at: Children's National Hospital Pediatric clinic (Natella Rakhmanina); the Senior Deputy Director of the DC Department of Health HAHSTA (Clover Barnes); Family and Medical Counseling Service (Rita Aidoo); Georgetown University (Princy Kumar); The George Washington University Biostatistics Center (Tsedenia Bezabeh, Vinay Bhandaru, Asare Buahin, Nisha Grover, Lisa Mele, Alla Sapozhnikova, Greg Strylewicz, and Marinella Temprosa); The George Washington University Department of Epidemiology (Shannon Barth, Morgan Byrne, Amanda Castel, Alan Greenberg, Shannon Hammerlund, Paige Kulie, Anne Monroe, Lauren O'Connor, James Peterson, Jonathon Rendina, Su Yadana, and Martin Zavala) and Department of Biostatistics and Bioinformatics; The George Washington University Medical Faculty Associates (Jose Lucar); Howard University Adult Infectious Disease Clinic (Jhansi L. Gajjala) and Pediatric Clinic (Sohail Rana); Kaiser Permanente Mid-Atlantic States (Michael Horberg); La Clinica Del Pueblo (Suyanna Barker); Washington Health Institute, formerly Providence Hospital (Jose Bordon); Unity Health Care (Gebeyehu Teferi); Us Helping Us, People Into Living, Inc. (DeMarc Hickson); Veterans Affairs Medical Center (Debra Benator and Rachel Denyer); Washington Hospital Center (Adam Klein); and Whitman-Walker Institute (Stephen Abbott).

The DC Cohort is funded by the National Institute of Allergy and Infectious Diseases, 1R24AI152598-01.

Publications and Presentations

2024 

Yang Z, Liang H, Liu H, Barth S, Byrne M, Andersen E, Bhandaru V, Castel A on behalf of DC Cohort. Model Checking for Logistic Models with Study of Telehealth During the COVID-19 Pandemic Among PWH in DC. 2024. Journal of the International Chinese Statistical Association - Statistics in Biosciences. Published online on September 2024. doi: 10.1007/s12561-024-09457-2. (Link to manuscript)

Byrne ME, Resnik JB, Hotberg MA, Greenberg AE, Castel AD, Monroe AK. Factors associated with time to initial antiretroviral regimen discontinuation in the DC Cohort. 2024. AIDS Research ad Human Retroviruses. Published on June 2024. doi: 10.1089/AID.2024.0002 (Link to manuscript)

Barth SK, Kulie P, Monroe AK, Horberg MA, Castel AD, on behalf of the DC Cohort Executive Committee. Prevalence and Risk Factors for Long COVID among a Cohort of Persons with HIV in Washington, DC. 2024. AIDS Care. Published online June 11, 2024. doi:10.1080/09540121.2024.2357811 (Link to manuscript)

Barth SK, Monroe AK, Houston P, Benator D, Horberg M, Castel AD, DC Cohort Executive Committee. COVID-19 Incidence, Risk Factors, Impact, and Related Stigma among a Cohort of Persons with HIV in Washington, DC. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2024 May 6:10-97. doi: 10.1097/QAI.0000000000003447 (Link to manuscript)

 Manghani P, Monroe A, Castel A, Kumar P, Phunmongkol J, Denyer R, O'Connor L on behalf of the DC Cohort Executive Committee. Low Uptake of Long-Acting Injectables in the first 2.5 years following approval among a Cohort of People living with HIV. Open Forum Infectious Diseases , Volume 11, Issue 5, May 2024, ofae087, https://doi.org/10.1093/ofid/ofae087 (Link to manuscript)

O'Connor LF, Byrne M, Baskaran A, Andersen EW, Horberg MA, Benator DA, Lucar J, Denyer RV, Lee R, Castel AD, Monroe AK; DC Cohort Executive Committee. Characterizing Indicators of Engagement in HIV-Associated Healthcare and Clinical Outcomes among People with HIV and Mpox in Washington, DC: A Nested Case-Control Study of the DC Cohort. Pathogens. 2024 Jan 27;13(2):117. doi: 10.3390/pathogens13020117. PMID: 38392854; PMCID: PMC10892472. (Link to manuscript)

Andersen EW, Kulie P, Castel AD, Lucar J, Benator D, Greenberg AE, Monroe A; DC Cohort Executive Committee. Mpox Awareness, Risk Reduction, and Vaccine Acceptance among People with HIV in Washington, DC. Pathogens. 2024 Jan 28;13(2):124. doi: 10.3390/pathogens13020124. PMID: 38392862; PMCID: PMC10891655. (Link to manuscript)

Byrne M, Monroe AK, Doshi RK, Horberg MA, Castel AD; DC Cohort Executive Committee. A Latent Class Analysis of Substance Use and Longitudinal HIV RNA Patterns among PWH in DC Cohort. AIDS and Behavior. 2024 Feb 6. doi: 10.1007/s10461-023-04257-z. (Link to manuscript) 

Stewart B, Byrne M, Levy M, Horberg MA, Monroe AK, Castel AD; DC Cohort Executive Committee. The Association of Mental Health and Substance Use with Retention in HIV Care among Black Women in Washington, District of Columbia. Women's Health Issues. 2024 Jan 5. doi: 10.1016/j.whi.2023.11.003. (Link to manuscript)

2023

Barish N, Barth S, Monroe AK, Greenberg AE, Castel AD; DC Cohort Executive Committee. Site Assessment Survey to Assess the Impact of the COVID-19 Pandemic on HIV Clinic Site Services and Strategies for Mitigation in Washington, DC. BMC Health Services Research. 2023 Oct 20. doi: 10.1186/s12913-023-10069-7. (Link to manuscript)

Barth SK, Saulters KJ, Balba GP, Monroe AK, Horberg MA, Kumar PN, Greenberg AE, Castel AD; DC Cohort Executive Committee. Mixed Methods Analysis of Telehealth Experience, Satisfaction, and Quality of Care During the COVID Pandemic Among Persons with HIV in Washington, DC. AIDS and Behavior. 2023 Oct 24. doi: 10.1007/s10461-023-04198-7. (Link to manuscript)

Malipeddi VP, Levy M, Byrne M, Monroe A, Happ LP, Moeng LR, Castel AD, Horberg M, Wilcox R; DC Cohort Executive Committee. Evaluation of New Hypertension Guidelines on the Prevalence and Control of Hypertension in a Clinical HIV Cohort: A Community-Based Study. AIDS Res Hum Retroviruses. 2023 Aug 1. doi: 10.1089/AID.2022.0063. (Link to manuscript) 

Ramirez HC, Monroe AK, Byrne M, O'Connor LF. Examining the Association Between a Modified Quan-Charlson Comorbidity Index and HIV Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants. AIDS Res Hum Retroviruses. 2023 Jul 27. doi: 10.1089/AID.2022.0186. (Link to manuscript)

Elf JL, Horn K, Abroms L, Stanton CA, Cohn AM, Spielberg F, Gray T, Harvey E, Debnam C, Kierstead L, Levy ME, Castel A, Monroe A, Niaura R. Prevalence and Correlates of Cardiovascular, Pulmonary, Cancer, and Mental Health Comorbidities Among Adults With HIV Who Smoke. J Assoc Nurses AIDS Care. 2023 Jul-Aug 01. doi: 10.1097/JNC.0000000000000416. (Link to manuscript)

Castel AD, Barth S, Wilbourn BC, Horberg M, Monroe AK, Greenberg AE; DC Cohort Executive Committee. Trends in COVID-19 Vaccine Hesitancy and Uptake among Persons Living with HIV in Washington, DC. J Acquir Immune Defic Syndr. 2023 Jun 26. doi: 10.1097/QAI.0000000000003243. (Link to manuscript)

Monroe AK, Kulie PE, Byrne ME, Wilbourn B, Barth SK, Resnik JB, Huebner DM, Horberg MA, Castel AD, Greenberg AE. Psychosocial Impacts of the COVID-19 Pandemic from a Cross-Sectional Survey of People Living with HIV in Washington, DC. AIDS Res Ther. 2023 May 30. doi: 10.1186/s12981-023-00517-z. (Link to manuscript)

Akselrod H, Byrne M, Lundberg J, Czeresnia JM, Lucar J, Secco A, Levy M, Monroe A, Castel A, Horberg M, Doshi R, Rivasplata H, Squires L, Parenti D, Benator D; DC Cohort Executive Committee. Improvements in Virologic Control Among PWH Over Time: Narrowing the Gap Between Those With and Without STIs. AIDS Behav. 2023 Feb;27(2):673-677. doi: 10.1007/s10461-022-03802-6. (Link to manuscript)

Jaurretche M, Byrne M, Happ LP, Levy M, Horberg M, Greenberg A, Castel AD, Monroe AK; DC Cohort Executive Committee. HIV Care Continuum Outcomes among recently diagnosed people with HIV (PWH) in Washington, DC. Epidemiol Infect. 2023 Jan 30:1-19. doi: 10.1017/S0950268823000043. (Link to manuscript)

 

2022

Harp R, Byrne M, Monroe A, Castel A. Housing, HIV outcomes, and related comorbidities in persons living with HIV in Washington, DC. AIDS Care. 2022 November 30. doi: 10.1080/09540121.2022.2151557. (Link to manuscript) 

Hodges J, Caldwell S, Cohn W, Flickinger T, Waldman AL, Dillingham R, Castel A, Ingersoll K. Evaluation of the Implementation and Effectiveness of a Mobile Health Intervention to Improve Outcomes for People With HIV in the Washington, DC Cohort: Study Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc. doi: 10.2196/37748. (Link to manuscript)

Monroe AK, Xiao J, Greenberg AE, Levy ME, Temprosa M, Resnik JB, Castel AD; DC Cohort Executive Committee. Risk of Severe COVID-19 Disease and the Pandemic's Impact on Service Utilization Among a Longitudinal Cohort of Persons with HIV-Washington, DC.AIDS Behav. 2022 Apr 13. doi: 10.1007/s10461-022-03662-0. (Link to manuscript)

Monroe AK, Polyak CS, Castel AD, Esber AL, Byrne ME, Maswai J, Owuoth J, Maganga L, Bahemana E, Adamu Y, Iroezindu M, Kibuuka H, Kiweewa F, Greenberg AE, Crowell TA, Ake JA, DC Cohort Executive Committee and AFRICOS Study Group. Clinical similarities and differences between two large HIV cohorts in the United States and Africa. PLoS One. 2022 April 4. doi: 10.1371/journal.pone.0262204. (Link to manuscript)

Koay WLA, Xiao J, Temprosa M, Happ LP, Monroe AK, Castel AD, Rakhmanina NY; DC Cohort Executive Committee. Outcomes of Dual Versus Triple Antiretroviral Drug Regimens Among Virally Suppressed Adults in the DC Cohort. AIDS Res Hum Retroviruses. 2022 Mar 23. doi: 10.1089/aid.2021.0202. (Link to manuscript)

Byrne M, Akselrod H, Monroe AK, Horberg M, Lucar J, Castel AD, Denyer R, Doshi R, Secco A, Squires L, Schroeter S, Benator D. Identifying Geographic Areas of Washington, DC, With Increased Potential for Sexual HIV Transmission Among People With HIV With STIs and Concurrent Elevated HIV RNA: Data From the DC Cohort. Open Forum Infect Dis. 2022 Mar 18. doi: 10.1093/ofid/ofac139. (Link to manuscript)

 

2021

Monroe AK, Levy M, Greenberg AE, Keruly JC, Moore RD, Horberg MA, Kulie P, Mohanraj BS, Kumar P, Castel AD; DC Cohort Executive Committee. Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts. Open Forum Infectious Diseases. 2021 August. doi: https://doi.org/10.1093/ofid/ofab338. (Link to manuscript)

Wilbourn B, Saafir-Callaway B, Jair K, Wertheim J, Laeyendecker O, Jordan JA, Kharfen M, Castel AD. Characterization of HIV Risk Behaviors and Clusters Using HIV-TRACE Among a Cohort of Persons Living with HIV in Washington, DC. AIDS Research and Human Retroviruses. 2021 June 22. Ahead of Print. doi: http://doi.org/10.1089/AID.2021.0031. (Link to manuscript)

Koay W, Dirajlal-Fargo S, Levy M, Kulie P, Monroe AK, Castel AD, Rakhmanina N; DC Cohort Executive Committee. Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth with Perinatal Human Immunodeficiency Virus in the DC Cohort. Open Forum Infectious Diseases. 2021 July. doi: https://doi.org/10.1093/ofid/ofab308. (Link to manuscript)

Jaurretche M, Levy M, Castel AD, Happ LP, Monroe AK, Wyche KF; DC Cohort Executive Committee. Factors Influencing Successful Recruitment of Racial and Ethnic Minority Patients for an Observational HIV Cohort Study in Washington, DC. J Racial Ethn Health Disparities. 2021 March 15. doi: 10.1007/s40615-021-01015-6. Epub ahead of print. PMID: 33721291. (Link to manuscript)

Doshi RK, Byrne M, Levy M, Varga L, Kuo I, Horberg MA, Castel AD, Monroe AK; DC Cohort Executive Committee. Association of Substance Use Disorders with Engagement in Care and Mortality among a Clinical Cohort of People with HIV in Washington, DC. AIDS Behav. 2021 Feb 1. doi: 10.1007/s10461-021-03157-4. Epub ahead of print. PMID: 33521909. (Link to manuscript)

Arnold JD, Byrne ME, Monroe AK, Abbott SE; District of Columbia Cohort Executive Committee. The Risk of Anal Carcinoma After Anogenital Warts in Adults Living With HIV. JAMA Dermatol. 2021 Jan 13:e205252. doi: 10.1001/jamadermatol.2020.5252. Epub ahead of print. PMID: 33439220; PMCID: PMC7807394. (Link to manuscript)

 

2020

Happ LP, Monroe AK, Young HA, Ma Y, Greenberg AE, Horberg MA, Castel AD. Individual- and clinic-level factors associated with achieving glycemic control in a large cohort of people with HIV in care-Washington, D.C [published online ahead of print, 2020 Jun 8]. J Acquir Immune Defic Syndr. 2020;10.1097/QAI.0000000000002416. doi:10.1097/QAI.0000000000002416. (Link to manuscript)

Wallace DE, Horberg MA, Benator DA, Greenberg AE, Castel AD, Monroe AK, Happ LP; DC Cohort Executive Committee. Diabetes mellitus control in a large cohort of people with HIV in care-Washington, D.C. AIDS Care. 2020 Aug 18:1-11. doi: 10.1080/09540121.2020.1808160. Epub ahead of print. PMID: 32811173. (Link to manuscript)

Levy ME, Monroe AK, Horberg MA, Benator DA, Castel AD; DC Cohort Executive Committee. Is low-level viraemia associated with serum lipid profiles among HIV controllers? HIV Med. 2020 Aug;21(7):e14-e16. doi: 10.1111/hiv.12856. Epub 2020 Apr 20. PMID: 32311819; PMCID: PMC7354203. (Link to manuscript)

Spence AB, Levy ME, Monroe A, Castel A, Timpone J, Horberg M, Adams-Campbell L, Kumar P. Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. J Community Health. 2021 Feb;46(1):75-85. doi: 10.1007/s10900-020-00844-6. PMID: 32424501. (Link to manuscript)

Levy ME, Griffith C, Ellenberger N, Monroe AK, Castel AD, Rakhmanina N. DC Cohort Executive Committee. Outcomes of Integrase Inhibitor-Based Antiretroviral Therapy in a Clinical Cohort of Treatment-Experienced Children, Adolescents and Young Adults with HIV Infection. Pediatr Infect Dis J. 2020. Epub 2020/05. doi: 10.1097/INF.0000000000002577. (Link to manuscript)

Goldstein D, Hardy WD, Monroe A, Hou Q, Hart R, Terzian, A. Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis. BMC Public Health. 2020;20(1):509. Published 2020 Apr 16. doi:10.1186/s12889-020-08631-7. (Link to manuscript)

Opoku J, Doshi RK, Castel AD, Sorensen I, Horberg M, Allston A, Kharfen M, Greenberg AE. Comparison of Clinical Outcomes of Persons Living with HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study. JMIR Public Health Surveill 2020;6(2):e16061. doi: 10.2196/1606. PubMed PMID: 32293567. (Link to manuscript)

Levy ME, Ma Y, Magnus M, Younes N, Castel AD, DC Cohort Executive Committee. Cholesterol-Lowering Effect of Statin Therapy in a Clinical HIV Cohort: An Application of Double Propensity Score Adjustment. Ann Epidemiol. 2020. doi: https://doi.org/10.1016/j.annepidem.2020.02.005. (Link to manuscript)

George JM, Kuriakose SS, Monroe A, Hou Q, Byrne M, Pau AK, Masur H, Hadigan C, Castel AD, Horberg MA; DC Cohort Executive Committee. Utilization of Direct Oral Anticoagulants in People with HIV: Observational Data from the DC Cohort. Clin Infect Dis. 2020 Mar 17;71(10):e604–13. doi: 10.1093/cid/ciaa284. Epub ahead of print. PMID: 32179901; PMCID: PMC7744993. (Link to manuscript)

Gibson KM, Bendall ML, Jair K, Jordan JA, Castel AD, Wilbourn B, Crandall KA, Pérez Losada M, DC Cohort Executive Committee. A Cross-Sectional Study to Characterize HIV-1 Dynamics in Washington DC Using Next-Generation Sequencing. Sci Rep. 2020; 10(1):1989. (Link to manuscript)

Secco AA, Akselrod H, Czeresnia J, Levy M, Byrne M, Monroe A, Lucar J, Horberg M, Castel AD, Doshi R, Rivasplata H, Squires L, Parenti D, Benator D, DC Cohort Executive Committee. Sexually Transmitted Infections in Persons Living with HIV Infection and Estimated HIV Transmission Risk: Trends Over Time from the DC Cohort. Sexually Transmitted Infections 2020. Epub 2020/01/06.doi:10.1136/sextrans-2019-054216. PubMed PMID: 31907326. (Link to manuscript)

 

2019

Monroe AK, Powers Happ L, Rayeed N, Ma Y, Jaurretche MJ, Terzian AS, Trac K, Horberg MA, Greenberg AE, Castel AD, DC Cohort Executive Committee. Clinic-Level Factors Associated with Time to Antiretroviral Initiation and Viral Suppression in a Large Urban Cohort.Clinical Infectious Diseases 2019. Epub 2019/11/08.doi:10.1093/cid/ciz1098. PubMed PMID: 31701144. (Link to manuscript)

Levy ME, Monroe AK, Horberg MA, Benator DA, Molock S, Doshi RK, Powers Happy L, Castel AD. Pharmacologic Treatment of Psychiatric Disorders and Time with Unsuppressed HIV Viral Load in a Clinical HIV Cohort.  J Acquir Immune Defic Syndr. 2019. Epub 2019/07/24. doi: 10.1097/QAI.0000000000002138. PubMed PMID: 31356466. (Link to manuscript) 

Doshi S, Ucanda M, Hart R, Hou Q, Terzian AS, DC Cohort Executive Committee. Incidence and Risk Factors for Renal Disease in an Outpatient Cohort of HIV-Infected Patients on Antiretroviral Therapy. Kidney International Reports 2019. Epub 2019/05/07. doi: 10.1016/j.ekir.2019.04.024.  PubMed PMID: 31440698. (Link to manuscript)

Jair K, McCann CD, Reed H, Castel AD, Perez-Losada M, Wilbourn B, Greenberg AE, Jordan JA, DC Cohort Executive Committee. Validation of Publicly-Available Software Used in Analyzing NGS Data for HIV-1 Drug Resistance Mutations and Transmission Networks in a Washington DC Cohort. PLoS One. 2019;14(4):e0214820. Epub 2019/04/09. doi: 10.1371/journal.pone.0214820. PubMed PMID: 30964884. (Link to manuscript)

Gibson KM, Steiner MC, Kassaye S, Maldarelli F, Grossman Z, Pérez-Losada M, Crandall KA. A 28-year History of HIV-1 Drug Resistance and Transmission in Washington, DC. Front. Microbiol. 2019. Epub 2019/03/08. doi: 10.3389/fmicb.2019.00369. PubMed PMID: 30906285. (Link to manuscript)

Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV. AIDS Research and Human Retroviruses 2019;35:81-91. Epub 2019/01/11. doi: 10.1089/AID.2018.0145. PubMed PMID: 30353737; PMCPMC6343189.(Link to manuscript)

 

2018

Terzian A, Younes N, Greenberg AE, Opoku J, Hubbard J, Powers Happ L, Kumar P, Jones RR, Castel AD, DC Cohort Executive Committee. Identifying Spatial Variation Along the HIV Care Continuum: The Role of Distance to Care on Retention and Viral Suppression. AIDS Behav. 2018. Epub 2018/04/01. doi: 10.1007/s10461-018-2103-8. PubMed PMID: 29603112. (Link to manuscript)

Castel AD, Terzian A, Opoku J, Powers Happ L, Younes N, Kharfen M, Greenberg AE, DC Cohort Executive Committee. Defining Care Patterns and Outcomes Among Persons Living with HIV in Washington, DC: Linkage of Clinical Cohort and Surveillance Data.JMIR public health and surveillance. 2018;4(1):e23. Epub 2018/03/20. doi: 10.2196/publichealth.9221. PubMed PMID: 29549065; PMCPMC5878363. (Link to manuscript)

Lucar J, Hart R, Rayeed N, Terzian A, Weintrob A, Siegel M, Parenti DM, Squires LE, Williams R, Castel AD, Benator DA, DC Cohort Executive Committee. Sexually Transmitted Infections among HIV-Infected Individuals in the District of Columbia and Estimated HIV Transmission Risk: Data from the DC Cohort. Open Forum Infectious Diseases. 2018;5(2):ofy017. Epub 2018/02/27. doi: 10.1093/ofid/ofy017. PubMed PMID: 29479550; PubMed Central PMCID: PMCPMC5804762. (Link to manuscript)

Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Evaluation of Statin Eligibility, Prescribing Practices, and Therapeutic Responses Using ATP III, ACC/AHA, and NLA Dyslipidemia Treatment Guidelines in a Large Urban Cohort of HIV-Infected Outpatients.AIDS Patient Care STDS. 2018;32(2):58-69. Epub 2018/03/22. doi: 10.1089/apc.2017.0304. PubMed PMID: 29561173; PubMed Central PMCID: PMCPMC5808384. (Link to manuscript)

 

2017

Pérez-Losada M, Castel AD, Lewis B, Kharfen M, Cartwright CP, Huang B, Maxwell T, Greenberg AE, Crandall KA, DC Cohort Executive Committee. Characterization of HIV Diversity, Phylodynamics and Drug Resistance in Washington, DC. PLoS One. 2017;12(9):e0185644. Epub 2017/09/30. doi: 10.1371/journal.pone.0185644. PubMed PMID: 28961263; PubMed Central PMCID: PMCPMC5621693. (Link to manuscript) 

Castel AD, Terzian A, Hart R, Rayeed N, Kalmin MM, Young HA, Greenberg AE, DC Cohort Executive Committee. Use of National Standards to Monitor HIV Care and Treatment in a High Prevalence City-Washington, DC. PLoS One. 2017;12(10):e0186036. Epub 2017/10/06. doi: 10.1371/journal.pone.0186036. PubMed PMID: 28982127; PubMed Central PMCID: PMCPMC5628915. (Link to manuscript)

Asamsama OH, Squires L, Tessema A, Rae E, Hall K, Williams R, Benator D. HIV Nurse Navigation: Charting the Course to Improve Engagement in Care and HIV Virologic Suppression. Journal of the International Association of Providers of AIDS Care. 2017;16(6):603-7. Epub 2017/10/12. doi: 10.1177/2325957417732835. PubMed PMID: 29017375. (Link to manuscript)

Aldous AM, Castel AD, Parenti DM, DC Cohort Executive Committee. Prevalence and Trends in Transmitted and Acquired Antiretroviral Drug Resistance, Washington, DC, 1999-2014. BMC Res Notes. 2017;10(1):474. Epub 2017/09/13. doi: 10.1186/s13104-017-2764-9. PubMed PMID: 28893321; PubMed Central PMCID: PMCPMC5594524. (Link to manuscript)

Levy ME, Greenberg AE, Hart R, Powers Happ L, Hadigan C, Castel AD, DC Cohort Executive Committee. High Burden of Metabolic Comorbidities in a Citywide Cohort of HIV Outpatients: Evolving Health Care Needs of People Aging with HIV in Washington, DC. HIV Med. 2017;18(10):724-35. Epub 2017/05/16. doi: 10.1111/hiv.12516. PubMed PMID: 28503912; PubMed Central PMCID: PMCPMC5643214. (Link to manuscript)

 

2016

Castel AD, Kalmin MM, Hart RL, Young HA, Hays H, Benator D, Kumar P, Elion R, Parenti D, Ruiz ME, Wood A, D'Angelo L, Rakhmanina N, Rana S, Bryant M, Hebou A, Fernández R, Abbott S, Peterson J, Wood K, Subramanian T, Binkley J, Happ LP, Kharfen M, Masur H, Greenberg AE. Disparities in Achieving and Sustaining Viral Suppression among a Large Cohort of HIV-Infected Persons in Care Washington, DC. AIDS Care. 2016;28(11):1355-64. Epub 2016/06/15. doi: 10.1080/09540121.2016.1189496. PubMed PMID: 27297952; PubMed Central PMCID: PMCPMC5084086. (Link to manuscript)

Rakhmanina N, Lam KS, Hern J, Young HA, Walters A, Castel AD. Interruptions of Antiretroviral Therapy in Children and Adolescents with HIV Infection in Clinical Practice: A Retrospective Cohort Study in the USA. J Int AIDS Soc. 2016;19(1):20936. Epub 2016/11/01. doi: 10.7448/ias.19.1.20936. PubMed PMID: 27797320; PubMed Central PMCID: PMCPMC5087211. (Link to manuscript)

Greenberg AE, Hays H, Castel AD, Subramanian T, Powers Happ L, Jaurretche M, Binkley J, Kalmin MM, Wood K, Hart R, DC Cohort Executive Committee. Development of a Large Urban Longitudinal HIV Clinical Cohort Using a Web-Based Platform to Merge Electronically and Manually Abstracted Data from Disparate Medical Record Systems: Technical Challenges and Innovative Solutions. Journal of the American Medical Informatics Association: JAMIA. 2016;23(3):635-43. Epub 2016/01/02. doi: 10.1093/jamia/ocv176. PubMed PMID: 26721732; PubMed Central PMCID: PMCPMC4901378. (Link to manuscript)

2024

Barth SK, Ji YS, Yeung E, Byrne M, Horberg M, Monroe AK, Castel AD, on behalf of the DC Cohort Executive Committee. "Incidence and Risk Factors for Neurocognitive Disorders Among Persons with HIV in Washington, DC." Poster. CROI 2025. San Francisco, CA. March 9-12, 2025

O'Connor L, Hammerlund S, Mele L, Jaurretche M, Hickson D, Denyer D, Greenberg A, Castel A, Monroe A on behalf of the DC Cohort Executive Committee. "Viral Non-Suppression Among PWH Diagnosed at an Older Age: Implications for Secondary HIV Prevention." Poster. CROI 2025. San Francisco, CA. March 9-13, 2025.

O'Connor L, Monroe A, Denyer R, Castel A, Magnus M on Behalf of the DC Cohort Executive Committee. "Clinical and HIV Surveillance Data to Determine Care Status for People with HIV in Washington, DC." Poster. CROI 2025. San Francisco, CA. March 9-14, 2025.

Ji Y, Barth S, Castel AD (presenting), Ogunbajo A, Oke T, Horberg M, Monroe AK, on behalf of the DC Cohort Executive Committee. "DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC." Oral. CROI 2025. San Francisco, CA. March 9-15, 2025.

Denyer R, Byrne M, Nance C, Seeger D, Rakhmanina N, Monroe A, Benator D. "Dolutegravir with Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes." Poster. CROI 2025. San Francisco, CA. March 9-16.

 

Williams RM, Byrne M, Tammemagi CM, Sangraula A, Ahn J, Zhou X, Kim C, Mandelblatt J, Monroe A, Castel A. "HIV and Risk of Lung Cancer: Preparing to Implement Optimized Lung Cancer Screening for People with HIV." Presentation. CFAR Scientific and Community Symposium. New York, NY. October 29, 2024  (Poster PDF)  (Presentation PDF)  

Jadallah H, O'Connor L, Byrne M, Baskaran A, Horberg M, Castel A, Monroe A on behalf of the DC Cohort Executive Committee. "Understanding the impact of antiretroviral therapy and other factors on HPV clearance in cisgender women with HIV/HPV co-infections in the DC Cohort, 2016-2023." Poster. 2024 STI Prevention Conference. Atlanta, GA. September 16-19, 2024. (Poster PDF)

Byrne M, Koay WLAK, Unternaher J, O'Connor L, Monroe A, Denyer R, Castel A, Rakhmanina N, on behalf of the DC Cohort Executive Committee. "Long-term virologic outcomes of oral two-drug vs three-drug antiretroviral regimens in children, adolescents and adults living with HIV" Poster. 2024 ID Week 2024. Los Angeles, CA. October 16-19, 2024. (Poster PDF)

Hee Kim JY, O'Connor LF, Ji YS, Byrne M, Horberg MA, Castel AD, Monroe AK on behalf of the DC Cohort Executive Committee. "Characterizing STI Testing Disparities Between Asian PWH and Other Race/Ethnic Sub-Populations in the DC Cohort During Pre- and Post-Pandemic Periods." Poster 76. 2024 STI Prevention Conference. Atlanta, GA. September 16-19, 2024. (Poster PDF)

Malone J., O’Connor L., Monroe A., Barth S., Denyer R., Horberg M., Castel A. on behalf of the DC Cohort Executive Committee. "Exploring differences in the association between mental health, viral suppression, and adherence by age and transmission risk among people living with HIV: results from the DC Cohort." Poster Presentation at AIDS 2024, the 25th International AIDS Conference. Munich, Germany. July 22-26, 2024. (Poster PDF)

O’Connor L, Kirby O, Castel AD, Caldwell S, Hammerlund S, Hodges J, Cohn W, Ingersoll K, on behalf of the DC Cohort-PositiveLinks Study Group. "Clinical and Mental Health Characteristics, Social Determinants, and Mobile Phone Use of an Urban Cohort of PWH Enrolled in a Care Engagement/mHealth Efficacy Trial." Accepted for poster presentation at: International Association of Providers of AIDS Care Adherence Conference, Fajardo, Puerto Rico, June 9-11, 2024. (Poster PDF)

Hodges J, Cohn W, Castel AD, Freitas G, Hammerlund S, Caldwell S, Ingersoll K, on behalf of the DC Cohort-PositiveLinks Study Group. "Site Characteristics and Provider Readiness to Implement Change for an mHealth Hybrid Efficacy-Implementation Trial to Improve PWH Engagement in Care and Viral Suppression." Accepted for poster presentation at: International Association of Providers of AIDS Care Adherence Conference, Fajardo, Puerto Rico, June 9-11, 2024. (Poster PDF)

Castel AD, O’Connor L, Caldwell S, Kirby O, Hammerlund S, Park S, Hodges J, Cohn W, Ingersoll K, on behalf of the DC Cohort-PositiveLinks Study Group. "Baseline Clinical Characteristics and Care Continuum Outcomes among an Urban Cohort of PWH in a Care Engagement mHealth Efficacy Trial." Accepted for poster presentation at: International Association of Providers of AIDS Care Adherence Conference, Fajardo, Puerto Rico, June 9-11, 2024. (Poster PDF)

Barth S, Kulie P, Andersen E, Banas J, Baskaran A, Monroe AK, Castel AD, on behalf of the DC Cohort Executive Committee. "New HIV Diagnoses and Community Viral Load During the COVID-19 Pandemic in Washington, DC." Accepted for poster presentation at: International Association of Providers of AIDS Care Adherence Conference, Fajardo, Puerto Rico, June 9-11, 2024. (Poster PDF)

Kulie P, Baskaran A, Barth A, Andersen E, Banas J, Monroe AK, Castel AD, on behalf of the DC Cohort Executive Committee. "Missed Opportunities for HIV Prevention During the COVID-19 Pandemic." Accepted for poster presentation at: International Association of Providers of AIDS Care Adherence Conference, Fajardo, Puerto Rico, June 9-11, 2024. (Poster PDF)

Temprosa M, Monroe A, Greenberg A, Castel A. "A dynamic risk model for joint modelling of immune and metabolic health among people living with HIV and Diabetes in the DC Longitudinal Cohort." Poster Presentation at the European Diabetes Epidemiology Group 58th Annual Meeting Conference. Pesaro, Italy. April 20-23, 2024. (Poster PDF)

Castel AD, Mele L, Temprosa E, Kulie P, Barth S, Monroe AK, Rhodes A on behalf of the DC Cohort Executive Committee. "Linkage of the DC Cohort Longitudinal HIV Cohort Data to DC Department of Health Surveillance Data Using the ATra TM Black Box." Poster Presentation at the 26th International Workshop on HIV and Hepatitis Observational Databases. Vilamoura, Portugal. March 21 - 23, 2024. (Poster PDF)

O'Connor L, Resnik J, Simmens S, Bhandaru V, Wingate L, Greenberg AE, Benator D, Castel AD, Monroe AK on behalf of the DC Cohort Executive Committee. "Application of STOPP Criteria in an Urban Cohort of People Aging With HIV." (Poster 915), Poster Presentation at the 31st Conference on Retroviruses and Opportunistic Infections. Denver, Colorado. March 3 - 6, 2024. (Poster PDF)

2023

O'Connor L, Byrne M, Andersen E, Benator D, Lucar J, Horberg MA, Denyer R, Lee R, Castel AD, Monroe AK on behalf of the DC Cohort Executive Committee. "Characterizing Engagement in Care and STI Screening Among DC Cohort Participants with HIV and Mpox: A Nested Case-Control Study." (Poster 1501), Poster Presentation at IDWeek 2023. Boston, Massachusetts. October 11 - 15, 2023. (Poster PDF)

Lee J, Byrne M, Monroe A, Castel A, Horberg M, Kumar P, Spence A on behalf of the DC Cohort Executive Committee. "Implementation of HCV Treatments among People Living with HIV/HCV in Washington, DC." (Poster EPB0128), Poster Presentation at the 12th IAS Conference on HIV Science. Brisbane, Australia (Hybrid). July 23 - 26, 2023. (Poster PDF)

Barth S, Kulie P, Monroe AK, Horberg MA, Castel A on behalf of the DC Cohort Executive Committee. "Prevalence and Risk Factors for Post-Acute Sequelae of COVID among Persons with HIV in Washington, DC." (Oral Presentation 1037), Oral Presentation at the 18th International Conference on HIV Treatment and Prevention Adherence. Puerto Rico. June 11 - 13, 2023. (Oral Presentation) 

Byrne M, O'Connor L, Horberg MA, Castel A, Monroe AK on behalf of the DC Cohort Executive Committee. "Evaluating the Impact of Substance Use on Viral Suppression and Self-Reported ARV Adherence among PWH, DC Cohort." (Poster 1073), Poster Presentation at the 18th International Conference on HIV Treatment and Prevention Adherence. Puerto Rico. June 11 - 13, 2023. (Poster PDF) 

Castel A, Andersen E, Barth S, Horberg MA, Monroe AK on behalf of the DC Cohort Executive Committee. "8-Year Trajectories in an Urban Cohort of PWH Receiving Care - Washington, DC." (Poster 1079), Poster Presentation at the 30th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 19 - 22, 2023. (Poster PDF)

Castel A, Andersen E, Barth S, Horberg MA, Monroe AK on behalf of the DC Cohort Executive Committee. "Multistate Modelling of Care Patterns in a Longitudinal Cohort of PWH - Washington, DC." (Poster 1084), Poster Presentation at the 30th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 19 - 22, 2023. (Poster PDF)

Castel A, Andersen E, Monroe A, Lucar J, Lee R, Benator D, Greenberg A on behalf of the DC Cohort Executive Committee. "MPOX Awareness, Risk Reduction, and Vaccine Acceptance among a Cohort of PWH, Washington, DC." (Poster 1004), Poster Presentation at the 30th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 19 - 22, 2023. (Poster PDF)

 

2022

Castel AD, Barth SK, Horberg MA, Xiao JK, Greenberg AE, Monroe AK on behalf of the DC Cohort Executive Committee. "Disruptions in the HIV Care Continuum During the COVID-19 Pandemic." (Poster 009400), Poster Presentation at the 29th Conference on Retroviruses and Opportunistic Infections. Virtual. February 12 - 16, 2022. (Poster PDF)

Varga LM, Byrne M, Temprosa M, Bauder L, Horberg MA, Rodriguez-Diaz C, Monroe A, Castel A on behalf of the DC Cohort Executive Committee. "Latinos Living with HIV in DC: An Intersectional Approach Exploring Health Outcomes." (Poster 00774), Poster Presentation at the 29th Conference on Retroviruses and Opportunistic Infections. Virtual. February 12 - 16, 2022. (Poster PDF)

Denyer R, Byrne M, Monroe AK, Semeniuk O, Mele L, Strylewicz G, Bhandaru V, Raibee A, Popielski L, Cummins S, Benator DA on behalf of the DC Cohort Executive Committee. "Frequency and Characteristics of Hepatitis B Viremic Episodes in a Large Prospective Longitudinal U.S. Cohort of Persons with HIV." (Poster 2719), Poster presentation at ASM Microbe 2022. Washington, DC. June 9 - 13, 2022. (Poster PDF)

Ramirez HC, Byrne M, O'Connor LF, Monroe AK on behalf of the DC Cohort Executive Committee. "Examining the Association Between a Modified Quan-Charlson Comorbidity Index (QCCI) and Viral Suppression: A Cross-Sectional Analysis of DC Cohort Participants." Poster presentation at the Annual American Public Health Association Meeting. Boston, MA. November 6 - 9, 2022. (Poster PDF)

Lauren O’Connor, MPH; La’Marcus Wingate, PharmD, PhD; Sam Simmens, PhD, Amanda Castel, MD, MPH; Anne Monroe MD, MSPH. "Quality of Life in Older and Younger People with HIV and Diabetes." Poster presentation at the 17th International Conference on HIV Treatment and Prevention Adherence. Washington, DC. November 7 - 9, 2022. (Poster PDF) 

Balba G, Saulters K, Horberg M, Greenberg A, Monroe AK, Castel AD, Kumar P, Barth SK on behalf of the DC Cohort Executive Committee. "Telehealth Experience and Satisfaction During the COVID-19 Pandemic Among PWH in DC." (Poster 1032), Poster presentation at the 17th International Conference on HIV Treatment and Prevention Adherence. Washington, DC. November 7 - 9, 2022. (Poster PDF)

Barth SK, Xiao J, Monroe AK, Horberg M, Houston P, Benator D, Castel AD on behalf of the DC Cohort Executive Committee. "High Incidence of COVID-19 Infection and Related Stigma among a Cohort of PWH in Washington, DC." (Oral Presentation 1033), Oral Presentation at the 17th International Conference on HIV Treatment and Prevention Adherence. Washington, DC. November 7 - 9, 2022. (Oral Presentation) 

O'Connor L, Simmens S, Castel A, Byrne M, Monroe A, On behalf of the DC Cohort Executive Committee. "Patient Reported Mental Health and Stigma among People with HIV in the DC Cohort." Oral Presentation at the 13th Annual International Conference on Stigma. Washington, DC. November 15 - 18, 2022. 

 

2021

Moeng LR, Byrne M, Monroe A, Mallipeddi VP, Horberg MA, Castel A, Wilcox R. "The Association between Low Nadir CD4/CD8 and Cardiovascular Disease and Non-AIDS Associated Cancers in the DC Cohort." Poster Presentation at the 28th Conference on Retroviruses and Opportunistic Infections. Virtual. March 2021. (Poster PDF) 

 

2020

Elf JL, Horn K, Abroms L, Stanton C, Cohn A, Spielberg F, Gray T, Harvey E, Sanchez D, Debnam C, Castel AD, Greenberg A, Monroe A, Niaura R, on behalf of the DC Cohort Executive Committee. “Cigarette smoking among HIV-infected adults with comorbid medical conditions in a large HIV cohort (2011-2017) in Washington, D.C.” Poster presentation at the Society for Research on Nicotine and Tobacco, New Orleans LA, March 2020. (Poster PDF)

Akselrod H, Byrne B, Monroe AK, Levy ME, Denyer R, Klein A, Horberg MA, Castel AD, Doshi RK, Secco A, Lucar J, Squires L, Schroeter S, Benator DA. "Geographic Estimate of Sexual HIV Transmission Burden in Era of U=U: DC Cohort Data." (Poster 1133),Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Boston MA, March 2020. (Poster PDF) 

Byrne M, Monroe AK, Powers Happ LJ, Doshi RK, Horberg MA, Castel AD. “Latent Class Analysis of Substance Use and HIV VL Trajectory Patterns among PWH in DC.” (Poster 891), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Boston MA, March 2020.(Poster PDF) 

Dirajlal-Fargo S, Koay WLA, Levy ME, Monroe AK, CastelAD, Rakhmanina N. "Effect of Integrase Inhibitors on Weight Gain in Children and Adolescents." (Poster 0826), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Boston MA, March 2020. (Poster PDF)

 

2019

Jaurretche M, Byrne M, Powers Happ L, Levy ME, Horberg MA, Greenberg AE, Castel AD, Monroe AK, on behalf of the DC Cohort Executive Committee. “HIV Care Continuum Outcomes among Newly Diagnosed PLWH in Washington, DC.” (Poster 1320), Poster Presentation at IDWeek 2019, Washington DC, October 2019. (Poster PDF) 

Monroe AK, Levy ME, Greenberg AE, Moore RD, Keruly JC, Horberg MA, Mohanraj S, Kumar P, Castel AD, on behalf of the DC Cohort Executive Committee. “Differences Between Individuals Currently Taking Integrase Inhibitor (INSTI)-Based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-Line Therapy.” (Poster 2492), Poster Presentation at IDWeek 2019, Washington DC, October 2019. (Poster PDF)

Powers Happ L, Monroe AK, Young HA, Ma Y, Greenberg AE, Benator DA, Horberg MA, Castel A, on behalf of the DC Cohort Executive Committee. “The Impact of Glycemic Control on CD4 Cell Count in Persons Living with HIV and Diabetes Mellitus—Washington, DC.” (Poster 342), Poster Presentation at IDWeek 2019, Washington DC, October 2019. (Poster PDF) 

Akselrod H, Secco A, Lucar J, Levy M, Byrne M, Monroe AK, Horberg MA, Castel AD, Doshi RK, Rivasplata H, Squires L, Parenti D, Benator DA, on behalf of the DC Cohort Executive Committee. “Incident STIs among PLWH in Washington, DC: Measuring HIV Transmission Risk.” (Poster 849), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF)  

Doshi R, Byrne M, Levy M, Varga L, Kuo I, Horberg MA, Castel AD, Monroe AK, on behalf of the DC Cohort Executive Committee. “Substance Use Disorders Associated with Mortality Among HIV+ In Washington, DC.” (Poster 880), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF)

Kuriakose S, George J, Monroe AK, Hou Q, Pau AK, Masur H, Hadigan C, Castel AD, Horberg MA, on behalf of the DC Cohort Executive Committee. “Direct Oral Anticoagulant and ART Usage in PLWH: Data from the DC Cohort.” (Poster 641), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF)

Opoku J, Castel AD, Doshi R, Allston A, Greenberg AE, Kharfen M, on behalf of the DC Cohort Executive Committee. “Comparing Clinical Outcomes of Persons Living with HIV Who Have and Have Not Been Enrolled in a Large Longitudinal HIV Cohort Study in Washington, DC.” (Poster 6014), Poster Presentation at the National HIV Prevention Conference, Atlanta GA, March 2019. (Poster PDF)

Levy M, Monroe AK, Horberg MA, Benator DA, Molock S, Doshi RK, Powers Happ L, Castel AD, on behalf of the DC Cohort Executive Committee. “Treatment of Psychiatric Disorders and Time with HIV Viral Load > 200 copies/mL.” (Poster 700), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF)

Mohanraj SB, Hou Q, Monroe AK, Kassaye S, on behalf of the DC Cohort Executive Committee. “Six Years of Integrase Inhibitor Use in a Metropolitan City.” (Poster 0906), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF)

Spence AB, Levy ME, Monroe AK, Timpone J, Castel AD, Horberg MA, Kumar K, on behalf of the DC Cohort Executive Committee. “Cancer Incidence Among a Cohort of Persons Receiving HIV Care in Washington, DC.” (Poster 290), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, March 2019. (Poster PDF) 

Castel AD, Wilbourn B, Wertheim JO, Jordan JA, Jair K, Greenberg AE, on behalf of the DC Cohort Executive Committee. “Detection and Characterization of HIV Clusters Using HIV-TRACE among a Cohort of Persons Living with HIV in Washington, DC.” National HIV Prevention Conference (NHPC), Atlanta GA, 2019. (Poster PDF)

 

2018

Secco A, Akselrod H, Lucar J, Rayeed N, Leighton N, Parenti D, Benator DA on behalf of the DC Cohort Executive Committee. “Sexually Transmitted Infections among Persons Living with HIV Infection and Receiving Care in the District of Columbia: Time with Viral Load above 1500 as Proxy for Risk of Transmission.” (Poster 1498), Poster Presentation at Infectious Disease Society of America (IDSA), San Francisco CA, 2018. (Poster PDF)

George JM, Kuriakose SS, Monroe AK, Hou Q, Pau AK, Masur H, Hadiagan C, Castel AD, Horberg MA on behalf of the DC Cohort Executive Committee. “Increasing Utilization of Direct Oral Anticoagulants (DOACs) and Drug Interaction in People Living with HIV on Antiretroviral Therapy (ART): Data from the DC Cohort.” Poster Presentation at the 20thInternational Workshop on Co-Morbidities and Adverse Drug Reactions in HIV, New York NY, 2018. (Poster PDF)

Levy ME, Greenberg AE, Magnus M, Younes N, Castel AD, on behalf of the DC Cohort Executive Committee. “Immunosuppression and HIV Viremia Associated with Increased Atherogenic Cholesterol Concentrations in Older People with HIV.” (Poster TUPEB125), Poster Presentation at the XXII International AIDS Conference, Amsterdam Netherlands, July 2018. (Poster PDF)

Rakhmanina N, Levy ME, Ellenberger N, Griffith C, Monroe AK, Castel AD, on behalf of the DC Cohort Executive Committee. “Outcomes of Integrase Inhibitor-Based ART in Treatment-Experienced Children, Adolescents and Young Adults with HIV Infection.” (Poster 37), Poster Presentation at the 10th Workshop on HIV Pediatrics, Amsterdam Netherlands, July 2018. (Poster PDF)

Wilbourn BC, Greenberg AE, Kassaye S, Parenti D, Serlin M, Goldstein D, Hardy D, Teferi G, Hebou A, Benator D, Kumar P, Fernandez R, Bordon J, Castel AD, on behalf of the DC Cohort Executive Committee. “Behaviors Associated with Ongoing Transmission Risk among Recently Diagnosed and Chronically-Infected Persons Living with HIV in Washington, DC.” (Poster 179), Poster Presentation at the International Conference on HIV Treatment and Prevention Adherence, Miami FL, June 2018. (Poster PDF)

Castel AD, Powers Happ L, Monroe A, Jaurretche M, Terzian A, Greenberg AE on behalf of the DC Cohort Executive Committee. “Individual and Site-Level Factors Associated with Risk of Death among People with HIV.” (Poster 892), Poster Presentation at Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2018. (Poster PDF)

Levy ME, Greenberg AE, Magnus M, Younes N, Castel AD, on behalf of the DC Cohort Executive Committee. “Statin Coverage in an HIV Cohort: Comparison of ATP III, ACC/AHA, and NLA Guidelines.” (Poster 690), Poster Presentation at Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2018. (Poster PDF)

Monroe AK, Rayeed N, Jaurretche M, Powers Happ L, Trac K, Terzian A, Greenberg AE, Castel AD, on behalf of the DC Cohort Executive Committee. “Clinic-Level Factors Associated with Time to Viral Suppression in Washington, DC.” (Poster 1123), Poster Presentation at Conference on Retroviruses and Opportunistic Infections, Boston MA, February 2018. (Poster PDF) 

 

2017

Kalmin MM, Greenberg AE, Castel AD, Young H, Hoffman HJ, on behalf of the DC Cohort Executive Committee. “Association between Four Measures of Retention in Care and Virologic Failure.” (Poster 1503), Poster Presentation at Conference on Retroviruses and Opportunistic Infections, Seattle WA, February 2017. (Poster PDF)

Terzian A, Younes N, Opoku J, Hubbard J, Jones RR , Kumar P, Castel AD, on behalf of the DC Cohort Executive Committee. “Spatial Variation along the HIV Care Continuum in Washington, DC 2014-2015.” (Poster 905), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, February 2017. (Poster PDF)

 

2016

Levy ME, Greenberg AE, Hart RD, Powers Happ L, Hadigan C, Castel AD, on behalf of the DC Cohort Executive Committee. “High Burden of Metabolic Comorbidities in a Citywide Cohort of HIV Outpatients: Evolving Health Care Needs of People Aging with HIV in Washington, DC.” (Oral Presentation 06), Oral Presentation at the 7th International Workshop on HIV and Aging, Washington DC, September 2016 (Oral Presentation)

 

2015

Castel AD, Kalmin MM, Hart RD, Greenberg AE, Masur H, on behalf of the DC Cohort Executive Committee. “Identifying and Prioritizing Hepatitis C Treatment for HIV-Hepatitis C Co-Infection.” (Poster 660), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Seattle WA, February 2015. (Poster PDF)

Asamsama OH, Tessema A, Squires LE, Hall K, Benator DA. “HIV Nurse Navigation: Charting the Course to Improve Retention in Care and HIV Virologic Suppression.” Poster Presentation at The American Conference for the Treatment of HIV (ACTHIV), Dallas TX, April-May 2015. (Poster PDF)

Teran R, Balamane M, Nigam N, Umans J, Timpone J, Kumar P, Kassaye S. “Chronic Kidney Disease among HIV and HIV/HCV Co-Infected Individuals in Washington, DC.” Abstract Presentation at Kidney Week, San Diego CA, November 2015. (Poster PDF).

Ucanda M, Hart RD, Gajjala J, Doshi S, on behalf of the DC Cohort Executive Committee. “Examining the Risk for Acute Kidney Injury in HIV-Infected Adults Concurrently using Diuretics and Tenofovir Disoproxil Fumarate in Washington, DC Clinics.” (Poster 1654), Poster Presentation at the Infectious Disease Society of America (IDSA), San Diego CA, October 2015. (Poster PDF).

Lucar J, Hart RD, Weintrob A, Siegel M, Parenti D, Benator DA, for the DC Cohort Executive Committee. “Sexually Transmitted Infections among HIV Infected Patients Receiving Care in the District of Columbia: Incidence and Correlates of Syphilis, Gonorrhea, Chlamydia and Viral Hepatitis in the DC Cohort.” (Poster 1697), Poster Presentation at the Infectious Disease Society of America (ISDA), San Diego CA, October 2015. (Poster PDF).

Aldous AM, Castel AD, Parenti DM, on behalf of the DC Cohort Executive Committee. “Prevalence and Trends in Transmitted and Acquired Antiretroviral Drug Resistance in Washington, DC, 1999-2014.” (Poster 387), Poster Presentation at the Infectious Disease Society of America (ISDA), San Diego CA, October 2015. (Poster PDF)

Castel AD, Opoku J, Powers Happ L, Kharfen M, Greenberg AE, Younes N, on behalf of the DC Cohort Executive Committee. “Increasing the Completeness of HIV Public Health Surveillance and Clinical Research Databases: Linkage of District of Columbia Surveillance Data with DC Cohort Study Data-Washington, DC.” (Poster 2306), Poster Presentation at the CDC’s National HIV Prevention Conference, Atlanta GA, December 2015. (Poster PDF)

Balamane M, Teran R, Timpone J, Umans JG, Kumar P, Kassaye S. “HCV Independently Affects Kidney Function among HIV Co-Infected Individuals.” Abstract Presentation at Kidney Week, San Diego CA, November 2015. (Abstract PDF)

 

2014

Castel AD, Greenberg AE, Young HA, Kalmin MM, on behalf of the DC Cohort Executive Committee. “Disparities in Viral Suppression among a Large Cohort of HIV-Infected Persons in Washington, DC.” (Poster 993), Poster Presentation at Conference on Retroviruses and Opportunistic Infections, Boston MA, March 2014. (Poster PDF)

Castel AD, Greenberg AE, Kalmin MM, Young HA, on behalf of the DC Cohort Executive Committee. “Use of National Standards to Monitor HIV Care and Treatment in a High Prevalence City – Washington, DC.” (Poster 998), Poster Presentation at the Conference on Retroviruses and Opportunistic Infections, Boston MA, March 2014. (Poster PDF) 

 

2012

Castel AD, on behalf of the DC Cohort Executive Committee. “Implementation of a City-Wide Cohort of HIV-Infected Persons in Care in Washington DC: The DC Cohort.” (DC #A-452-0146-08025), Poster Presentation at The International AIDS Conference, Washington DC, July 2012. (Poster PDF)

Research Collaboration Opportunities

The DC Cohort welcomes collaboration with authorized internal and external users of the data to allow for a broad spectrum of data and research purposes.

WHO IS AUTHORIZED TO USE DC COHORT DATA?

  1. DC Cohort Site Principal Investigators (PIs)
  2. Staff or fellows at a participating DC Cohort site 
    1. Must be sponsored by a DC Cohort Site PI
  3. Members of the DC Cohort Data and Statistics Coordinating Center (DSCC)
  4. Members of the DC Center for AIDS Research (CFAR)
    1. After discussion with the DC Cohort Site PI
  5. GW Staff
    1. Must be sponsored by a DC Cohort staff member
  6. GW Students 
    1. Must be sponsored by a DC Cohort GW faculty member
    2. Must utilize the data for the purposes of meeting educational research requirements (e.g., Master's theses or Doctoral dissertations) 
  7. Outside investigators who are sponsored by a DC Cohort Site PI or an authorized member of the DSCC

COLLABORATION PROCESS: COHORT-WIDE ANALYSIS

  1. Read the Collaboration Policies document. This document outlines the policies and procedures for obtaining, using, and publishing with DC Cohort data.
  2. Complete a Concept Sheet. This document succinctly outlines the data needed to complete your analysis. If you are requesting analytic support, you must indicate this here. Your completed Concept Sheet should be submitted via e-mail to Dr. Amanda Castel at [email protected]. Data sent to external requesters may be subject to de-identification and some data elements may not be available for such requests. 
  3. The Concept Sheet will undergo three separate, concurrent reviews. They are reviewed by the DC Cohort PI or her designee, members of the DSCC, and by a DSCC analyst for data availability and feasibility. This process may involve additional questions and/or requests for revisions prior to approval. Once finalized, all cohort-wide analyses are reviewed, approved, and prioritized by the DC Cohort. On average, this process can take 4-6 weeks from concept sheet submission to approval.
  4. Once approved, if you have requested analytic support, then you will be put in touch with the analyst assigned to your project and can begin regular communications to move forward with your analysis.  
  5. If you are part of an outside entity receiving DC Cohort data, then you will need to complete a Data Use Agreement and Data Management Plan. The DSCC will create custom data sets fit to your specifications. These will be sent to you along with accompanying documentation as soon as they are available.
Please note that once the concept sheet is approved, it takes approximately 4-6 weeks to receive the data.

 

COLLABORATION PROCESS: SITE-SPECIFIC ANALYSIS

  1. Read the Collaboration Policies document. This document outlines the policies and procedures for obtaining, using, and publishing with DC Cohort data.
  2. Complete a Concept Sheet. This document succinctly outlines the data needed to complete your analysis. If you are requesting analytic support, you must indicate this here. Your completed Concept Sheet should be submitted via e-mail to Dr. Amanda Castel at [email protected]. Data sent to external requesters may be subject to de-identification and some data elements may not be available for such requests. 
  3. The Concept Sheet will undergo two separate, concurrent reviews. They are reviewed by the DC Cohort PI or her designee for clinical relevance and by a DSCC analyst for data availability and feasibility. This process may involve additional questions and/or requests for revisions prior to approval. Once finalized, site-specific analyses are forwarded to the Executive Committee for their awareness.  On average, this process can take 4-6 weeks from concept sheet submission to approval.
  4. Once approved, if you have requested analytic support, then you will be put in touch with the analyst assigned to your project and can begin regular communications to move forward with your analysis. Please note, due to limited resources, cohort-wide analysis will have prioritization for analytic support from the DSCC.
  5. If you are part of an outside entity receiving DC Cohort data, then you will need to complete a Data Use Agreement and Data Management Plan. The DSCC will create custom data sets fit to your specifications. These will be sent to you along with accompanying documentation as soon as they are available.
Please note that once the concept sheet is approved, it takes approximately 4-6 weeks to receive the data.

AD HOC REQUESTS FOR INTERNAL PURPOSES

For internal requests such as grant proposals, clinical trials, etc. that involve site-specific data and can be confined to a count or list of available participants, an email request can be sent to Amanda Castel at [email protected]. If it is determined that the request is lengthy in nature or rises to the level of an analysis, then it may be determined that a concept sheet and data request form may be required following the processes described above. 

PUBLICATION

In order to ensure that all products meet the standards and specifications of the DC Cohort, prior to submission to either a journal, meeting, conference, etc., your final product must undergo a review process. E-mail your final draft to Amanda Castel at [email protected] along with all accompanying analytic code and your completed Data Analysis Plan. The DC Cohort Executive Committee reviews all abstracts, manuscripts, posters, etc., provides feedback to the authors, and approves final versions of cohort-wide analyses. Additionally, all analytic code for any analysis is reviewed by the DSCC. This process takes approximately 2-4 weeks, so please plan accordingly to allow sufficient time for review and approval prior to any submission deadlines.

The DC Cohort must be cited in all works. For manuscripts, the author line must end “on behalf of the DC Cohort Executive Committee.” Additionally, an acknowledgement section must list all participating DC Cohort members; see the "Investigator Information" section above for an updated acknowledgement list.

DC Cohort Variable List 
Title and Link
N (As of October 8, 2024)
Date Range
Main DC Cohort Database13,096January 2011 to Present
COVID Survey

COVID Survey = 2,308 (All respondents, English and Spanish)

Long COVID = 1,104 (Anyone who took the survey on or after February 28, 2022, the date the Long COVID questions were added, or took the standalone Long COVID survey)

October 2021 to June 2023 
MPOX Survey (Starts on p. 33 of the document)503 (Anyone who took the COVID survey on or after August 18, 2022, the date the MPOX questions were added)August 2022 to June 2023
Patient Reported Outcomes (PROs) Survey

1,191

participants have completed a baseline PROs survey as of October 1, 2024

May 2021 to Present
Newsletter

The DC Cohort is pleased to announce the launch of our study newsletter! In this newsletter, we highlight exciting research updates (such as posters presented at scientific conferences and recent publications in peer-reviewed journals); spotlight integral members of our DC Cohort team; and provide information and resources on DC Cohort substudies. Take a look at our newsletters below! 

Spring/Summer 2024 Newsletter (PDF)

Fall/Winter 2023 Newsletter (PDF)

Spring/Summer 2023 Newsletter (PDF)

Fall/Winter 2022 Newsletter (PDF)

Fall/Winter 2021 Newsletter (PDF) 

Spring 2021 Newsletter (PDF)

Spring 2020 Newsletter (PDF)

Contact

Shannon Hammerlund
DC Cohort Senior Research Coordinator
[email protected]
 

Shannon Hammerlund
DC Cohort Senior Research Coordinator
[email protected]
 

James Peterson, DC Cohort Community Activities Coordinator
[email protected]